Consultation on draft guidance recommending treatments for types of arthritis that affecting spine
NICE has today published draft guidance on adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira; Remsima, Celltrion), certolizumab pegol (Cimzia, UCB Pharma) and golimumab (Simponi, Merck Sharp & Dohme) – known as TNF-alpha inhibitors – for treating some types of inflammatory arthritis that affect the spine …more
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.